Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Jason Luke

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Luke, Jason

Item TypeName
Concept Programmed Cell Death 1 Receptor
Academic Article Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability.
Academic Article PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.
Academic Article Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
Academic Article The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Academic Article Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
Academic Article Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Academic Article Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
Academic Article The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Academic Article Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
Academic Article Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-a4ß7 and anti-PD1 antibodies.
Academic Article Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
Academic Article Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.
Academic Article Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma.
Academic Article KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Academic Article Considering adjuvant therapy for stage II melanoma.

Search Criteria
  • Cell Death